Pharmaceuticals

CONBA

CONBA released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 6.473 B (forecast CNY 8.421 B), actual EPS CNY 0.19 (forecast CNY 0.33)

CONBA released FY2026 Q1 earnings on April 22 Pre-Market BJT, actual revenue CNY 1.906 B, actual EPS CNY 0.078

CONBA released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 1.498 B, actual EPS CNY -0.045

CONBA to Release FY2025 Annual Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 8.421 B, EPS CNY 0.33

CONBA to Release FY2026 Q1 Earnings on April 23, Pre-Market BJT

CONBA released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue CNY 1.617 B, actual EPS CNY 0.0951

CONBA released FY2025 9 Months Earnings on October 28 Pre-Market BJT, Actual Revenue: CNY 4.976 B, Actual EPS: CNY 0.2213

CONBA to Release FY2025 Q3 Earnings on October 29, Pre-Market BJT

CONBA released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue CNY 3.358 B, actual EPS CNY 0.137

CONBA released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 1.674 B, actual EPS CNY 0.0622

CONBA FY2025 Semi-Annual Earnings Release on August 28, 2025 (BJT)

Jiangbei's Profits Decline as Former Controlling Shareholder Fails to Fulfill Its Promise

EVA Pharma and Konbabe Sign Strategic Supply Agreement

Konimex Obtains Pharmaceutical Registration Certificate for Throat Relief Lozenges

Kontron Biopharmaceuticals Releases 2024 Annual Report

Konin Pharmaceutical's Revenue and Net Profit Decreased in Q1 2025

CONBA released FY2025 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 1.685 B, actual EPS CNY 0.064

Konin Pharmaceutical Reports 5.21% YoY Net Profit Growth in 2024, Plans to Distribute 1.5 Yuan Cash Dividend per 10 Shares

CONBA released FY2024 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 6.515 B (forecast CNY 7.533 B), actual EPS CNY 0.25 (forecast CNY 0.29)

CONBA released FY2024 Q4 earnings on April 24 After-Market BJT, actual revenue CNY 1.602 B (forecast CNY 1.965 B), actual EPS CNY 0.0412 (forecast CNY 0.03)

600572

603896

600664

On April 3rd, Tmall Health, in collaboration with dozens of well-known domestic health supplement companies such as By-Health, Caltrate, Centrum, HPGC, 21st Century, CONBA, GNC, YANGYUAN, Shouxiangu, SenShan, and Nuohui, jointly launched the "Health Supplement Assurance Alliance." The alliance aims to promote standardization, normalization, and transparency in the health supplement industry, advocating for consumers to recognize the "blue hat" label when purchasing health supplements and to choose products that better meet the nutritional and health needs of Chinese people

36Kr

Shouxiangu

HPGC

YANGYUAN

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Tmall Health has joined dozens of brands to establish the "Health Supplement Assurance Alliance"

According to the Zhitong Finance APP, CONBA disclosed its third-quarter report for 2025, stating that the company's revenue for the first three quarters reached 4.976 billion yuan, a year-on-year increase of 1.27%; net profit attributable to the parent company was 584 million yuan, a year-on-year increase of 12.65%; net profit excluding non-recurring items was 431 million yuan, a year-on-year increase of 1.61%; basic earnings per share were 0.232 yuan

Zhitong

CONBA released its performance for the first three quarters, with a net profit attributable to shareholders of 584 million yuan, a year-on-year increase of 12.65%

CONBA announced that its wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. participated in the national 11th batch of centralized drug procurement, with adenosylcobalamin capsules expected to win the bid at a price of 3.81 yuan/box, supplying 8.3224 million capsules to provinces such as Sichuan, Hubei, and Ningxia. The procurement period is 3 years, with an agreed procurement volume of 2.62 million capsules. Winning the bid will promote product sales and market expansion, positively impacting the company's future operating performance

CONBA: Adenosylcobalamin capsules are expected to win the bid for the 11th batch of national centralized drug procurement

On October 17th, CONBA announced that the company's board of directors received a written resignation letter from Vice President Shen Qi, who applied to resign from the position due to work adjustments. After resigning as Vice President, Shen Qi will no longer serve as the company's Chief Investment Officer but will continue to hold the position of Chairman of the Board at the company's holding subsidiary, Zhejiang Chinese Medical University Traditional Chinese Medicine Decoction Pieces Co., Ltd. Shen Qi's resignation will take effect upon the board's receipt of the resignation letter

CONBA: Shen Qi resigns from the position of Vice President of the company

According to the Zhitong Finance APP, CONBA announced that the company recently received the "Acceptance of Registration Notice" issued by the National Association of Financial Market Institutional Investors (Zhong Shi Xie Zhu [2025] SCP252) and (Zhong Shi Xie Zhu [2025] MTN850). The association agreed to accept the company's registration of ultra-short-term financing bonds and medium-term notes. The registered amount for the company's ultra-short-term financing bonds is 1 billion yuan, and the registered amount for the medium-term notes is 1 billion yuan

CONBA: Ultra-short-term financing bonds and medium-term notes approved for registration

According to the Zhitong Finance APP, CONBA announced that the company recently received the "Drug Registration Certificate" for Linggui Zhugan Decoction Granules approved by the National Medical Products Administration (referred to as "NMPA"). Linggui Zhugan Decoction Granules are derived from Zhang Zhongjing's "Jinkui Yaolue" from the Han Dynasty and have the effects of warming Yang, transforming phlegm, strengthening the spleen, and promoting dampness. It is mainly used to treat phlegm and fluid retention due to insufficient middle Yang, with symptoms including fullness in the chest and flanks, dizziness, palpitations, shortness of breath with cough, a white and slippery tongue coating, and a wiry and slippery pulse. The prescription consists of Poria, Cinnamon Twig, Atractylodes, and Licorice

CONBA: Linggui Zhushen Decoction Granules have obtained a drug registration certificate

CONBA announced that in the first half of 2025, operating revenue was 3.358 billion yuan, a year-on-year decrease of 2.61%. Net profit was 354 million yuan, a year-on-year decrease of 7.48%

CONBA: Net profit of 354 million yuan in the first half of 2025, a year-on-year decrease of 7.48%

300026

002166

600557

002020

300158

The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising

Chase Sun

Layn

Kanion Pharmaceutical

JINGXIN

Zhendong Pharmacy

CONBA's wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. recently obtained the Drug Registration Certificate for Tranexamic Acid Tablets issued by the National Medical Products Administration, with a specification of 0.25g. Tranexamic Acid Tablets are mainly used to treat various bleeding conditions, and the original manufacturer is Daiichi Sankyo Company, Limited

CONBA's subsidiary Tranexamic Acid Tablets has obtained a drug registration certificate

According to the Zhitong Finance APP, CONBA announced that recently, its wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. (hereinafter referred to as "Hangzhou CONBA") received the drug registration certificate for Perindopril Amlodipine Tablets (III) issued by the National Medical Products Administration (hereinafter referred to as "NMPA")

CONBA: Perindopril and Amlodipine Tablets (Ⅲ) have obtained the drug registration certificate

CONBA(600572.SH)